Sandoz Articles
Who Is Roche After ?
2 December 1996
EUROPEAN AND LONDON STOCK COMMENT
25 November 1996
Fluvastatin Slows CAD Development; LCAS
25 November 1996
"Indian Combinations"
25 November 1996
Sandoz' Tavist Products "Effective" For Colds
18 November 1996
Board Election At CytRx
18 November 1996
First Approval for Miglitol In Holland
11 November 1996
Systemix Rejects Sandoz Bid
4 November 1996
EUROPEAN STOCK COMMENT
28 October 1996
Galanthamine Enters Ph III In USA For Alzheimer's
28 October 1996
Novartis Partners 9 Months Figures Disappoint
28 October 1996
Lilly Launches Zyprexa In Its First Markets
21 October 1996
Swiss Pharma Exports In 1995
21 October 1996
Sandoz, Knoll Buy Into Generics As Gehe Opts Out
21 October 1996
Sandoz To Sell Herbicide Unit To Progress Novartis Merger
14 October 1996
Fluvastatin Improves Antifungal Activity
14 October 1996
Quintiles Buys UK Contract Research Firm Innovex
14 October 1996
World OTC Market Growth Disappoints In 1995
14 October 1996
Investment, Profitability And Biotechnology
14 October 1996
Sandoz' Gene Therapy In Brain Cancer
7 October 1996
Sandoz To Double Sales Force
7 October 1996
EUROPEAN STOCK COMMENT
7 October 1996
Zyprexa Gains 1st Approvals In USA/EU For Schizophrenia
7 October 1996
SangStats Positive Data With Generic Ciclosporin
7 October 1996
"Progress On All Fronts" At Shire Pharmaceuticals
7 October 1996
Fears Of Delay To Novartis Merger
30 September 1996
S Africa Govt Slams Drug Firms Over AIDS Play Row
23 September 1996
Mixed Views On Roche After Poor Interims
23 September 1996
Statins Market In Europe Set For Growth, IMS Study Forecasts
23 September 1996
James Callahan Resigns From Ciba-Geigy
16 September 1996
MIDAS Trial Reopens Ca Channel Blocker Debate
16 September 1996
Sangstat Completes Bioequivalence Dosing Studies Of Ciclosporin
16 September 1996
Europe Stock Comment
16 September 1996
Europe Stock Comment
9 September 1996
Janssen Pharma's Futurum For Schizophrenia
9 September 1996
Swiss Companies Disappoint In '96 First Half
9 September 1996
Clarification Of Fluvastatin Cost Benefits
2 September 1996
Novartis Partners' Profits Rise Below Forecasts
2 September 1996
Novartis Makes Site Decisions
2 September 1996
PDL Share Price Plummets As Trial Disappoints
2 September 1996
Zeneca Files First European Seroquel Dossier
19 August 1996
High French Hospital Spending Hits Local Drugmakers
12 August 1996
Senior Management Appointments At Novartis UK
5 August 1996
Europe Stock Comment
5 August 1996
Dilemma For Imported Drugs In China
5 August 1996
First Efficacy Data With Sandoz' Exelon
5 August 1996
Promotion At Sandoz
29 July 1996
Fluvastatin Shows Greater Cost Benefits
29 July 1996
EUROPE STOCK COMMENT
29 July 1996
Resignation At T Cell Sciences
22 July 1996
**Stop Press**EU Approves Formation Of Novartis
22 July 1996
EUROPE STOCK COMMENT
22 July 1996
Strong Growth From Ciba In 1996 First Half
22 July 1996
Changes To Be Made To EU Competition Rules?
15 July 1996
Accelerating Growth At Half Year For Sandoz
15 July 1996
Europe stock comment
15 July 1996
Ziprasidone May Have Unique Neuroleptic Activity
8 July 1996
Novartis Ruling To Come Soon?
8 July 1996
Brazilian Investment By Drug Firms
8 July 1996
Europe Stock Comment
8 July 1996
Novartis Names Management
8 July 1996
EUROPE STOCK COMMENT
1 July 1996
First Appro Of Sertindole In UK; Launch Imminent
1 July 1996
Sandoz Sues Japanese Drugmakers
24 June 1996
Sandoz Offer For SyStemix Pending
17 June 1996
Tactical Diversity In The Evolving US Health Market
17 June 1996
Corporate Investment In Argentina 1994-1996
10 June 1996
FDA Reclassifies OTC Laxative Products
10 June 1996
Eruope Stock Comment
3 June 1996
Sandoz To Acquire Outstanding Stake In SyStemix
3 June 1996
Sanofi names Dutch MD
3 June 1996
Israel's Promedico To Set-Up Own Production
3 June 1996
Novartis' Japanese Management
27 May 1996
Lamisil approved in USA
20 May 1996
Europe Stock Comment
20 May 1996
Shire: An Emerging Firm With A Difference
20 May 1996
Novartis Appointments
13 May 1996
Europe Stock Comment
13 May 1996
Senior Managment Appointments At Novartis
13 May 1996
Europe Stock Comment
6 May 1996
Europe Stock Comment
29 April 1996
Novartis Gets Approval At Ciba And Sandoz AGMs
29 April 1996
....Nutrition Downturn And Currency Holds Sandoz Back
29 April 1996
Strong Swiss Franc Impacts On Ciba's 1st Quarter
29 April 1996
EUROPE STOCK COMMENT
22 April 1996
Pipeline Contains Two Blockbusters, Says W-L
22 April 1996
European Stock Comment
15 April 1996
Spain's Esteve Sees Independent Future
15 April 1996
What Future For Biotechnology At AHP?
15 April 1996
European Stock Comment
8 April 1996
Atypical Antipsychotic Cuts Schizophrenia Costs
8 April 1996
Novartis Will Be A Leading Player In OTC Market
8 April 1996
US FTC Probes 22 Drug Firms' Pricing
1 April 1996
Europe Stock Comment
1 April 1996
Bayer Details Near-Term Product Expectations
1 April 1996
Boeh Ingelheim Buys Slice Of SS Pharma
1 April 1996
Corporate Ranking - A New Order For 1995
1 April 1996
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
